HealthQuill Canada
Britain's AstraZeneca will invest $3.5 billion in the US, its largest market, to expand its research and manufacturing footprint by the end of 2026, according to a company statement.
Drugs Pharma

AstraZeneca to invest $570 million in Canada to boost innovation, clinical delivery

HQ Team January 26, 2025: Pharmaceutical giant AstraZeneca has announced plans to invest US$570 million in Canada over the next decade, positioning the.

Read More
Dancing has a positive effect on the “mood circuits” in the brain and can lower depression in people with Parkinson’s disease, according to an observational study on 23 patients conducted by Canada’s York University.
Drugs Health Medical

Dancing can help lower depression in people with Parkinson’s disease

Dancing has a positive effect on the “mood circuits” in the brain and can lower depression in people with Parkinson’s disease, according to.

Read More
ARS Pharmaceuticals, a US-based biopharmaceutical company, got the nation’s drug regulator’s approval for a nasal spray to treat allergic reactions in adult and paediatric patients.
Pharma

Danish Pharma ALK pays ARS $145m for Neffy nasal spray licensing deal

HQ Team November 13, 2024: ALK-Abelló, the Danish pharma company has acquired exclusive rights to Neffy (epinephrine nasal spray) from ARS Pharmaceuticals for.

Read More
The World Health Organization expects the first delivery of mpox vaccines, made by Bavarian Nordic and donated by the European Union, today in Congo — the outbreak's epicentre.
Drugs Health Pharma

First batch of Bavarian Nordic’s mpox vaccines in Congo by Sept. 5 

The World Health Organization expects the first delivery of mpox vaccines, made by Bavarian Nordic and donated by the European Union, today in.

Read More
Agilent Technologies Inc., will acquire Canada-based Biovectra, a contract development and manufacturing company, for $925 million, according to a company statement.
Drugs Health Pharma

US-based Agilent Technologies to acquire Canada’s Biovectra for $925m

HQ Team July 23, 2024: Agilent Technologies Inc., will acquire Canada-based Biovectra, a contract development and manufacturing company, for $925 million, according to.

Read More
AstraZeneca announced the completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, for $2.4 billion.
Drugs Health Pharma

AstraZeneca completes $2.4 billion acquisition of Fusion Pharma

AstraZeneca announced the completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, for $2.4 billion.

Read More
At least 75.9 million people were forced to flee their homes due to conflict, violence or disasters within their state’s borders in 2023, according to a UN report.
Climate Health Pharma

About 76 million people are internally displaced worldwide, says UN

HQ Team May 15, 2024: At least 75.9 million people were forced to flee their homes due to conflict, violence or disasters within.

Read More
Anglo-Swedish drugmaker, AstraZeneca will acquire clinical-stage Fusion Pharmaceuticals for $2 billion in cash to get access to the latter’s radioconjugates to treat cancer.
Drugs Health Pharma

AstraZeneca to acquire Fusion Pharmaceuticals for $2 billion in cash

HQ Team March 20, 2024: Anglo-Swedish drugmaker, AstraZeneca will acquire clinical-stage Fusion Pharmaceuticals for $2 billion in cash to get access to the.

Read More
Teenagers are using e-cigarettes at a rate higher than adults, and in England, the numbers have tripled in the past three years, according to the World Health Organization.
Drugs Health Pharma

Teenagers smoking e-cigarettes at a faster rate than adults: WHO

HQ Team December 15, 2023: Teenagers are using e-cigarettes at a rate higher than adults, and in England, the numbers have tripled in.

Read More
The WHO has reclassified the Covid-19 virus Omicron BA.2.86 mutation as a “variant of interest” after the global health agency reported an 8.9% rise in global prevalence in cases arising in the UK, France and Sweden.
Drugs Health Pharma

Omicron mutant BA.2.86 reclassified as ‘variant of interest’ by WHO 

HQ Team November 29, 2023: The WHO has reclassified the Covid-19 virus Omicron BA.2.86 mutation as a “variant of interest” after the global.

Read More